Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel- and lectin-based proteomics analyses

Authors

  • Jaime J. Jayapalan,

    1. Faculty of Medicine,, University of Malaya Centre for Proteomics Research, University of Malaya, Kuala Lumpur, Malaysia
    Search for more papers by this author
  • Keng L. Ng,

    1. Department of Surgery,, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
    Search for more papers by this author
  • Azad H. A. Razack,

    1. Department of Surgery,, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
    Search for more papers by this author
  • Onn H. Hashim

    Corresponding author
    1. Department of Molecular Medicine,, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
    • Faculty of Medicine,, University of Malaya Centre for Proteomics Research, University of Malaya, Kuala Lumpur, Malaysia
    Search for more papers by this author

Correspondence: Professor Onn H. Hashim, Department of Molecular Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

E-mail:onnhashim@um.edu.my

Fax: +603-7967-4957

Abstract

Diagnosis of prostate cancer (PCa) is currently much reliant on the invasive and time-consuming transrectal ultrasound-guided biopsy of the prostate gland, particularly in light of the inefficient use of prostate-specific antigen as its biomarker. In the present study, we have profiled the sera of patients with PCa and benign prostatic hyperplasia (BPH) using the gel- and lectin-based proteomics methods and demonstrated the significant differential expression of apolipoprotein AII, complement C3 beta chain fragment, inter-alpha-trypsin inhibitor heavy chain 4 fragment, transthyretin, alpha-1-antitrypsin, and high molecular weight kininogen (light chain) between the two groups of patients’ samples. Our data are suggestive of the potential use of the serum proteins as complementary biomarkers to effectively discriminate PCa from BPH, although this requires further extensive validation on clinically representative populations.

Ancillary